RC
KPRX icon

Rangeley Capital’s Kiora Pharmaceuticals KPRX Stock Holding History

Rangeley Capital’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.3K Buy
+10,000
New +$21.1K 0.02% 136

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Rangeley Capital's KPRX Position: Q1 2026 in Review

Rangeley Capital opened a new position in Kiora Pharmaceuticals (KPRX) in Q1 2026: 10,000 shares worth $19.3K. The stake represents 0.02% of the portfolio and ranks #136 among its holdings.

18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • Rangeley Capital held 10,000 shares of Kiora Pharmaceuticals worth $19.3K as of Q1 2026.
  • Kiora Pharmaceuticals was a new Rangeley Capital position in Q1 2026.
  • Kiora Pharmaceuticals made up 0.02% of Rangeley Capital's portfolio in Q1 2026, its #136 holding.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.